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Interleukin-12 is proposed to have anti-neoplastic
activity on the basis of both its anti-angiogenic and
immunologic effects. Gene gun therapy with inter-
leukin-12 cDNA into the peritumoral area of immuno-
competent 129/J mice with life-threatening primary
vascular tumors reduced tumor volume 7.5-fold and
almost tripled the duration of mouse survival, in
contrast with luciferase-bombarded control mice. Epi-
dermal expression of mouse interleukin-12 elevated
tumoral and serum levels of interferon-g and tumor
necrosis factor-a, increased the tumoral populations
Localized primary vascular tumors occur in 12% of infants,typically characterized by an often alarming rate ofexpansion during the first 6 mo of life. Despite theirrapid growth and potential for disfigurement, thesetumors are often not treated because of the side-effects
of available therapy and the tendency of the tumors to involute
spontaneously during the first decade of life. In 5%–10% of patients,
the rapid growth of these vascular tumors results in complications,
particularly skin ulceration, visual and airways obstruction, and
heart failure. Kasabach–Merritt syndrome is another life-threatening
complication of vascular endothelial cell tumors in infants, most
commonly in association with hemangioendotheliomas or tufted
angiomas (Enjolras et al, 1997; Enjolras and Mulliken, 1997).
Thrombocytopenia, microangiopathic anemia, and coagulopathy
are additional features, thought to relate to the rapid enlargement of
the tumor. Despite aggressive intervention with currently available
systemic medications, 20%–50% of infants affected by Kasabach–
Merritt syndrome die, often because of the bleeding diathesis.
Interleukin (IL)-12 has been shown to have both potent immune-
mediated anti-tumor effects (Brunda et al, 1993; Nastala et al, 1994;
Trinchieri, 1995), and anti-angiogenic effects (Voest et al, 1995).
These known actions suggest that IL-12 may be particularly well-
suited as a therapeutic agent for treating primary vascular tumors.
Manuscript received July 14, 1998; revised January 25, 1999; accepted
for publication February 2, 1999.
Reprint requests to: Dr. Amy S. Paller, Division of Dermatology #107,
Children’s Memorial Hospital, 2300 Children’s Plaza, Chicago, IL 60614.
Abbreviations: mIL-12, mouse interleukin-12; RLU, relative light units.
1Presented at the Society for Investigative Dermatology meeting, April
24, 1997 (Lannutti B, Sun W, Makkar H-P, Paller AS: In vivo IL-12 gene
therapy inhibits endothelial cell tumor growth in a mouse model. J Invest
Dermatol 108:546, 1997).
0022-202X/99/$10.50 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
775
of T lymphocyte and natural killer cells, and induced
tumor apoptosis. Gene transfer of interleukin-12 had
little effect on tumor volumes and survival of tumor-
bearing athymic nude mice, emphasizing the
requirement for T cell directed cellular immunity.
Peritumoral gene gun introduction of interleukin-12
may be a novel, cost-effective approach to limit the
growth and associated mortality of life-threatening
tumors. Key words: anti-neoplastic agents/gene therapy/
hemangioendothelioma/hemangioma/interleukin-12. J Invest
Dermatol 112:775–781, 1999
The systemic administration of recombinant IL-12 protein, how-
ever, causes concentration-dependent toxicity in the mouse (Orange
et al, 1995) and human (Lotze et al, 1996), and is tremendously
costly. Ex vivo transfection of the mouse IL-12 (mIL-12) gene into
mouse fibroblasts (Tahara et al, 1994) or tumor cells (Martinotti
et al, 1995; Cavallo et al, 1997; Nanni et al, 1998) using a retroviral
vector has resulted in inhibition of tumor growth, suggesting that
peritumoral IL-12 expression by gene therapy may be as effective
as systemic protein administration, but less toxic and significantly
more cost-effective.
Particle-mediated gene bombardment allows delivery of sub-
microgram amounts of DNA directly into the skin (Sun et al,
1995). Gene gun delivery of mIL-12 has recently been shown
to cause regression of primary and metastatic murine tumors
(Rakhmilevich et al, 1996). Using a mouse model of Kasabach–
Merritt syndrome (Hoak et al, 1971), we have demonstrated that
in vivo gene gun introduction of mIL-12 prevents the rapid
growth of a life-threatening, primary vascular tumor and increases
mouse survival.
MATERIALS AND METHODS
IL-12 gene expression vector A mouse IL-12 expression vector
(pWRG3169) containing coding sequences for the p35 and p40 subunits
of murine IL-12 (mIL-12) was constructed as described by Rakhmilevich
et al (1996), and kindly provided by Dr. N.-S. Yang (formerly at Powderjack,
Madison, WI). The IL-12 subunits are linked in tandem, each driven in a
sense direction by its own cytomegalovirus promoter. Luciferase (luc)
cDNA was subcloned into the NotI site of a pcDNA.3 plasmid (Invitrogen,
Carlsbad, CA), and also operated under the transcriptional control of a
cytomegalovirus promoter. Our laboratory has found that this luciferase
cDNA is expressed strongly in cultured EOMA cells (mouse hemangio-
endothelioma cell line; courtesy of Dr. Robert Auerbach, University of
Wisconsin, Madison, WI), as detected by luminometry (Brasier, 1994) after
transient transfection by either lipofection or gene gun bombardment.
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Murine tumor model All animal experiments were approved by the
Institutional Animal Care and Use Committee of the Children’s Memorial
Institute for Education and Research. Tumors were established by inocula-
tion of EOMA as previously described (Lannutti et al, 1997). Female
athymic nude (Harlan Sprague Dawley, Indianapolis, IN) and 129/J (Jackson
Laboratories, Bar Harbor, ME) mice were obtained at 6–8 wk of age.
EOMA cells were maintained in Dulbecco’s modified Eagle medium
supplemented with 10% fetal bovine serum. Nude or 129/J mice were
injected subcutaneously in the right flank with 106 EOMA cells, and tumor
growth was measured every other day by tissue calipers. Tumor volume
was determined as (width)2 3 length. Except for survival experiments,
mice were killed when tumors reached a diameter of 2 cm, or within 24 h
after lethargy, marked pallor, and cutaneous bruising was noted. Each
experiment was performed with at least six mice for each condition studied.
In all studies, untreated mice with EOMA tumors and tumor-bearing
mice treated with luc-containing vectors served as controls for mIL-12
treated mice.
In vivo gene transfer Plasmid DNA was precipitated on to 2.6 µm gold
particles, and mIL-12 or luciferase DNA was delivered at 350 psi using a
helium-pulse Accell gene gun (courtesy of Powderjack, Madison, WI)
(Rakhmilevich et al, 1996), beginning 24 h after tumors became visible.
Bombardment directly into the skin overlying tumors was avoided in an
effort to minimize the chance of tumor bleeding. Mice were bombarded
at four evenly spaced peritumoral sites (total delivery 5 µg DNA) every
other day for 1 wk.
Luminometry to detect luciferase expression in tumors treated with
sham control bombardments Twenty-four hours after bombardment
with luciferase cDNA, mice were killed. The tumor tissue was snap frozen
in liquid nitrogen. Extracts were prepared by addition of 0.5 ml extraction
buffer (0.5 M potassium phosphate, 2.5 mM phenylmethylsulfonyl fluoride,
1 mM dithiothreitol) to 0.5 g tumor tissue, followed by scissors mincing,
grinding, sonication, and centrifugation of cell debris. The crude extract
was analyzed by luminometry, as described by Cheng et al (1993), using a
Monolight 2001 luminometer (Analytical Luminescence Laboratories, San
Diego). Similarly treated frozen IL-12 bombarded skin was assays for
luciferase activity as a negative control, and luciferase was used as a
positive control.
Immunohistochemistry Lymphocyte subsets, natural killer cells, and
mIL-12 were detected in frozen tumor tissue sections using immunohisto-
chemical staining as previously described (Paller et al, 1988), using rat
monoclonal anti-CD8 or anti-CD4, mouse monoclonal anti-natural killer
cell, or rabbit polyclonal anti-mIL-12 antibodies (Pharmigen, Piscataway,
NJ), and detected by 39,39-diaminobenzidine-H2O2 staining. Mouse spleen
was used as positive control tissue.
Studies of apoptosis and cell proliferation were conducted as previously
described (Lannutti et al, 1997), using a Klenow FragEL DNA fragmentation
detection kit (Oncogene, Cambridge, MA) and a mouse monoclonal anti-
proliferating cell nuclear antigen antibody (DAKO, Carpinteria, CA),
respectively. The percentages of proliferative and apoptotic cells were
determined by counting a minimum of 2000 cells from separate sections
of the tumors and overlying epidermis of at least four mice under a light
microscope at 400 3 magnification.
Bioassays for mIL-12, mIFN-g, and mouse tumor necrosis factor-a
(mTNF-a) Serum and tissue levels of mIL-12, IFN-γ, and TNF-α were
determined at 24 h after each of the first two gene transfers by enzyme-
linked immunosorbent assay (ELISA) (IFN-γ and TNF-α assay kits from
R&D Systems, Minneapolis, MN; mIL-12 assay from Genzyme,
Cambridge, MA). To determine cytokine levels in overlying epidermis/
upper dermis and deep dermal/subcutaneous tumor samples, samples were
collected in 0.5 ml of extraction buffer (100 µM Pefabloc Plus (serine
protease inhibitor, Boehringer-Mannheim, Indianapolis, IN) and 1%
Triton-X100 in phosphate-buffered saline, minced, sonicated, and centri-
fuged. Supernatant was collected, and levels determined as above. Serially
diluted recombinant murine IL-12 (Genzyme), IFN-γ and TNF-α (R&D
Systems) were used as standards.
Cytokine-induced cell death assays on EOMA cells Cell viability
assays were performed using an LDH Viability Assay (Boehringer,
Mannheim, Germany). Briefly, 5 3 105 EOMA cells were plated on T75
plates (Falcon), and incubated in complete Dulbecco’s modified Eagle
medium with 10% fetal bovine serum (Sigma, Indianapolis, IN). Two
hours after plating, 100 U recombinant murine IFN-γ (Genzyme) per ml,
50–2000 U TNF-α (Genzyme) per ml, or 100 U IFN-γ per ml, and 50–
2000 U TNF-α per ml was incubated with the cells for 72 h. The number
of viable cells was determined by Trypan blue exclusion assay on cell
harvests. The number of dead cells was determined by mixing equal amounts
of conditioned supernatant and Viability Assay Developer (Boehringer-
Mannheim), then measuring the optical density using an ELISA reader
(Molecular Devices, Sunnyvale, CA). The percentage of live cells was
expressed as the number of live cells divided by the total number of live
and dead cells.
Determination of platelet levels and hematocrits Cell counts were
determined using a CellDyn Coulter counter (Abbott Laboratories, Abbott
Park, IL). Age-matched 129/J (n 5 4) without EOMA tumors were
studied to determine the normal range of values.
Statistical analysis Results are presented as mean 6 SD of the mean.
Differences between means were analyzed using the paired Student t-test.
p , 0.05 was considered statistically significant.
RESULTS
Gene gun delivery results in strong local epidermal expres-
sion of IL-12 Histologic examination of skin overlying the
EOMA tumor revealed that the gold particles primarily penetrated
epidermal cell layers and the upper dermis, but did not reach the
tumor cells. Southern analysis of the overlying epidermis showed
the presence of the mIL-12 gene 24 h after initial introduction
(data not shown). Immunohistochemical analysis of tissue sections
demonstrated strong IL-12 expression in the epidermis, with lower
but visible expression in dermal hair follicles (Fig 1a), in contrast
to lack of staining for IL-12 in luciferase-bombarded epidermis
(Fig 1b). In vivo expression of IL-12 was measured by ELISA in
overlying epidermis, tumor tissue, and serum, and compared with
the expression of a control vector with a luc cDNA expression
plasmid (Fig 1c). Significant expression of IL-12 was detected at
both 24 and 72 h after initial bombardment. mIL-12 was not
detected in the skin of luc-bombarded mice, although luminometry
measurements detected strong expression of luciferase in the epi-
dermis/upper dermis of luc-bombarded skin [mean 60 000 relative
light units (RLU), 200 times control RLU]. The RLU detected
by luminometry of the lower dermis/subcutaneous tissue with the
tumor in mice bombarded with luciferase was not greater than the
RLU detected in untreated control tumors. Neither luciferase nor
IL-12 was found in the skin of mice bombarded with beads only.
IL-12 was not found at 24 or 72 h after bombardment in the
tumor tissue or serum of IL-12 treated mice. The lower limit of
mIL-12 detection was 5 pg per ml.
Peritumoral mIL-12 gene therapy suppresses tumor growth
and increases mouse survival Tumors first became visible 6 d
after EOMA cell inoculation, and were treated with IL-12 cDNA
24 h later. By the completion of the four sets of bombardments,
7 d after the tumors first appeared, tumor volumes of luc-treated
tumors measured three times that of IL-12-treated tumors (Fig 2a).
By 17 d after EOMA cell injection, an age at which control mice
were dying, the tumor volume in control mice was
3000 6 242 mm3, whereas that of IL-12 treated mice was
460 6 46.8 mm3 (Fig 2a, b). The tumors that had been treated
for 1 wk with IL-12 cDNA began to grow after day 20, paralleling
the earlier slope of untreated or sham-treated control tumors. No
weight loss, irritability or lethargy was noted in mice given mIL-
12 therapy.
Mice that had been treated with the four bombardments of the
mIL-12 gene survived for a mean of 38.8 6 11.0 d after injection
of the EOMA cells, in contrast to a mean survival of 14.8 6 3.6 d
in luc treated control mice (p , 0.0005) (Fig 3). By the time that
all of the control mice had died (20 d), all of the mIL-12 treated
mice were still alive. Despite this increased survival, however, the
IL-12 treated mice did not show evidence of reversal of the
thrombocytopenia or anemia of Kasabach–Merritt syndrome.
Epidermal IL-12 expression triggers the expression of interferon
(IFN)-γ and TNF-α in tumor tissue: ELISA assays were performed
to measure the serum and tissue levels of cytokines other than IL-
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Figure 1. Gene gun transfer of mIL-12 results in strong epidermal
expression of mIL-12. Cryostat sections of frozen tumor taken from
mice treated with IL-12 cDNA or luciferase 24 h after gene gun delivery
were evaluated for expression of mIL-12. Sections were incubated with
rabbit anti-mIL-12, and expression detected by biotinylated rabbit anti-rat
IgG antibody, streptavidin–biotin–peroxidase system, and DAB-H2O2.
Strong staining of the epidermis was noted in all specimens of mice treated
with mIL-12 cDNA (a). Despite the presence of numerous beads in the
epidermis, IL-12 was not expressed in the epidermis of mice bombarded
with luciferase cDNA (b). At high pressure (350 psi), gold beads reached
dermal tissues, but dermal expression was not detected. Original
magnification, a, 3100; b, 3400. The epidermis and upper dermis of skin
overlying tumors was assayed for mIL-12 by ELISA assays 24 h after each
of the first two bombardments in luc treated (j) and mIL-12 treated (r)
mice (c). Luc treated control tissues demonstrated expression of luciferase
as detected by luminometry.
Figure 2. In vivo gene transfer of mIL-12 inhibits EOMA tumor
growth. (a) 129/J mice were injected subcutaneously in the right flank
with 106 EOMA cells. Tumors first became apparent at µ6 d after cell
implantation, and grew exponentially thereafter until mouse death. Gene
bombardment began 1 d after tumors were noted, and was performed
every other day for 1 wk. Tumor growth was measured every other day
by tissue calipers, and tumor volume determined as (width)2 3 length.
Tumor volume was monitored in at least six mice for each treatment
group, with untreated mice with EOMA tumors and tumor-bearing mice
treated with luc-containing vectors serving as controls for mIL-12 treated
mice. d, luc treated; u, mIL-12 treated. (b) At 17 d after tumor cell
inoculation, control mice were dying, with a mean tumor volume of
3000 6 242 mm3 (left), whereas IL-12 treated mice appeared healthy and
had a mean tumor volume of 460 6 46.8 mm3 (right).
12. By 24 and 72 h after the initial bombardment, levels of IFN-
γ in the tumor (Fig 4a) and serum (Fig 4b) were significantly
increased when compared with the low levels in luc treated mice.
Similarly TNF-α, which was undetectable in luc-treated mouse
samples, was detectable by ELISA assay in the tumor (Fig 5a) and
serum (Fig 5b) of IL-12 treated mice. The minimal detectable
concentrations serum concentrations were 4.0 pg per ml for TNF-α
and 2.0 pg per ml for IFN-γ.
The inhibitory effect of mIL-12 gene gun introduction on tumor
growth and increased survival requires competent T lymphocyte
immunity. Previous investigations with systemic administration of
IL-12 protein have provided evidence that the anti-tumor effect
of IL-12 is indirect and requires the proliferation and activation of
immune cells, particularly T cells, which produce effector cytokines
(Brunda et al, 1993; Nastala et al, 1994). Our immunohistochemical
staining of tissue from immunocompetent 129/J mice showed
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Figure 3. mIL-12 gene therapy increases survival of mice with
EOMA cell tumors. Mice that had been treated with the four
bombardments (arrows) of the mIL-12 gene survived for a mean of
38.8 6 11.0 d after injection of the EOMA cells, in contrast to a mean
survival of 14.8 6 3.6 d in luc treated control mice (p , 0.0005). At least
10 mice were included in each treatment group for survival studies. d, luc
treated; u, mIL-12 treated.
significantly increased numbers of CD81, CD41, and natural
killer cells in IL-12 treated tumor tissue (p , 0.01), as compared
with tumors in luc-treated mice at 24 h, 72 h (Fig 6), and 120 h
after the initial bombardment. To further elucidate the requirement
for T cell mediated immunity, we compared the efficacy of gene
gun introduction of mIL-12 in immunocompetent and T cell
deficient mice. Gene gun therapy with mIL-12 resulted in only
slight inhibition in tumor growth in nude mice (Fig 7). In addition,
the mean survival in treated mice was increased by only 2 d beyond
that of luc bombarded nude mice.
IFN-g and TNF-a act synergistically in causing EOMA cell
cytotoxicity In vitro studies showed that neither IFN-γ 100 U
per ml nor TNF-α as high as 2000 U per ml had any significant
cytotoxic effect on EOMA cells in vitro (Fig 8). The combination
of as low as 50 U TNF-α per ml and 100 U IFN-γ per ml caused
cytotoxicity, however, with 50% cell death of cells treated with
500 U TNF-α per ml and 100 U IFN-γ per ml.
The mechanism of IL-12 gene gun efficacy involves the
induction of apoptosis but not inhibition of proliferation
of tumor cells The tumor tissue of mIL-12-treated animals
demonstrated five times as many apoptotic tumor cells as luc-treated
animals (Fig 9) (p , 0.00001). The low level of apoptosis induced
by gene gun treatment with luc was not greater than that of
untreated, age-controlled tumors (p 5 0.04). In contrast, there was
no significant difference in the proliferative rate between luc-
treated (18.8% 6 5.6% of tumor cells) and mIL-12-treated tumors
(19.5% 6 7.5% of cells) as detected by proliferating cell nuclear
antigen staining (p . 0.7).
DISCUSSION
Particle bombardment (gene gun) is a rapid, painless technique for
in vivo gene introduction that avoids the expense of time-consuming
in vitro gene introduction and cell selection. The technique is ideal
for transient gene expression of secreted gene products, such as
cytokines, and allows the simultaneous introduction of more than
one gene. The gene (or genes) in an episomal vector is coated on
to gold beads, and propelled into tissue by helium pressure. As we
and others have shown (Lannutti et al, 1996), the majority of gene
expression after bombardment into intact mouse skin is seen in
epidermis. Little expression occurs in dermis despite the penetration
Figure 4. Gene gun therapy with mIL-12 leads to increased tumor
tissue and serum levels of mIFN-g. Tumor (a) and serum (b) levels of
IFN-γ were determined in at least four mice from each treatment group
at 24 h after each of the first two gene transfers by ELISA assay following
manufacturer’s instructions. Serially diluted recombinant murine IFN-γ
was used as a standard. j, luc treated; u, mIL-12 treated.
of the upper dermis of mouse skin by the gold bead, probably
because of the relative acellularity of dermis. In studies with human
skin, the penetration of the gold beads is limited to the epidermis,
providing the added advantage that the gold beads are all shed as
epidermal cells mature and are desquamated during the month after
the bombardment.
IL-12 protein amplifies the immune response by stimulating the
proliferation of natural killer and activated T cells, augmenting
cytolytic responses, and inducing the secretion of cytokines, particu-
larly of IFN-γ from natural killer cells and T cells and of TNF-α
from T cells and monocytic cells. Given that systemic administration
of IL-12 protein inhibits the growth of established subcutaneous
malignant tumors and experimental metastases (Brunda et al, 1993;
Hendrzak et al, 1995), we tested the efficacy of in vivo IL-12 gene
therapy in inhibiting the growth of a primary, nonmetastasizing
vascular tumor. Introduction of mIL-12 by gene therapy, rather
than administration of IL-12 protein, offers several theoretical
advantages. First, recombinant cytokine protein is extremely costly,
particularly based on the long duration (9 mo) of recommended
treatment for vascular tumors with another cytokine, IFN-α. In
addition, protein produced in the host cells is more likely to have
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Figure 5. Gene gun therapy with mIL-12 leads to increased tumor
tissue and serum levels of TNF-a. Tumor (a) and serum (b) levels of
TNF-α were determined in at least four mice from each treatment group
at 24 h after each of the first two gene transfers by ELISA assay following
manufacturer’s instructions. Serially diluted recombinant murine TNF-α
was used as a standard. j, luc treated; r, mIL-12 treated.
the proper secondary structure for activity. Finally, the increased
local concentration of protein produced within peritumoral cells
may result in less toxicity than systemically administered cytokine
protein (Colombo et al, 1996). We selected an mIL-12 expression
plasmid with p35 and p40 chains in tandem, each driven by its
own cytomegalovirus promoter, because of the high level of
expression with cytomegalovirus promoters and the 3–8-fold
increase in mIL-12 protein expression in vivo after gene gun
introduction as compared with the same cDNA clones in a single
operon with an internal ribosome entry site linkage (Rakhmilevich
et al, 1996).
Using the mouse model of the Kasabach–Merritt syndrome
(Hoak et al, 1971), we have shown that short-term introduction
of mIL-12 cDNA by gene gun inhibits tumor growth, and
significantly increases mouse survival. The major complication of
the Kasabach–Merritt syndrome is the bleeding associated with
the thrombocytopenia and coagulopathy. Surprisingly, neither the
average platelet count nor the hematocrit of the tumor-bearing
mice at 16 d of age differed in mIL-12-transfected and sham-
Figure 6. mIL-12 introduction by gene gun causes tumor tissue
infiltration with CD4F, CD8F, and natural killer cells. Cryostat
sections of frozen tumor were examined at 72 h after initiation of the
bombardments for cell infiltration of the tumor tissue. Tissue sections were
incubated with rat monoclonal primary anti-CD8 and anti-CD4 antibodies,
or with mouse monoclonal anti-natural killer cell antibody, and detected
using Vectastain kits. Mouse spleen was used as positive control tissue for
cell subset identification, whereas tumor treated with phosphate-buffered
saline and then secondary antibody served as a negative control. At least
four mice from each treatment group were evaluated. j, luc treated;
r, mIL-12 treated.
Figure 7. Tumor growth is not inhibited by mIL-12 gene
introduction in immunodeficient nude mice. Nude mice were injected
subcutaneously in the right flank with 106 EOMA cells. Tumors first
became apparent at µ 6 d after cell implantation, and grew exponentially
thereafter until mouse death. Gene bombardment began 1 d after tumors
were noted, and was performed every other day for 1 wk. Tumor growth
was measured every other day by tissue calipers, and tumor volume
determined as (width)2 3 length. Tumor volume was monitored in at least
four mice for each treatment group, with untreated mice with EOMA
tumors and tumor-bearing mice treated with luc-containing vectors serving
as controls for mIL-12 treated mice. All of the luc treated mice died by
16 d after tumor cell inoculation, and of the mIL-12 mice by 18 d. d, luc
treated; u, mIL-12 treated.
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Figure 8. IFN-g and TNF-a show a synergistic cytotoxic effect on
EOMA cells in vitro. EOMA cells were incubated with 0–2000 U TNF-
α per ml, and with or without 100 U IFN-γ per ml. Cells incubated with
TNF-α alone showed no decreased viability after 72 h incubation. Cells
incubated with 100 U IFN-γ per ml along with TNF-α showed a dramatic
decrease in viability, beginning at concentrations as low as 100 U TNF-α
per ml. u, TNF-α 1 IFN-γ (100 U per ml); d, TNF-α only.
Figure 9. mIL-12 gene gun treatment causes tumor cell apoptosis.
The percentage of apoptotic cells in tumor tissues was determined in
deparaffinized tumor sections 120 h after the initial bombardment using a
Klenow FragEL DNA fragmentation detection kit. Binding of biotinylated
nucleotides was detected by streptavidin–horseradish peroxidase followed
by H2O2/diaminobenzidine. Treatment of sections with 1 µg DNase I per
ml in Tris-buffered saline per 1 mM MgSO4 after the proteinase K
treatment served as a positive control, whereas substitution of water for
Klenow provided a negative control. The percentage of apoptotic cells
were determined by counting a minimum of 2000 cells from separate
sections of the tumors and overlying epidermis of at least four mice under
a light microscope at 4003 magnification. j, luc treated; r, mIL-12
treated; s , control mice with tumors, but no gene gun treatment, 12 d
after inoculation with EOMA cells.
transfected mice. Yet the mIL-12-transfected mice did not show
the cutaneous bruising nor other evidence of the bleeding tendency
that sham-transfected or untreated 129/J mice with tumors showed.
Furthermore, the survival was correlated with tumor size alone,
and not with platelet or hematocrit levels. These results suggest
that, in addition to the low platelet count and anemia, tumor size
and possibly other phenotypic characteristics contribute significantly
to death from the Kasabach–Merritt syndrome in the mouse model,
and that these factors may have been improved by mIL-12 therapy.
Gene gun delivery of the IL-12 cDNA results primarily in
epidermal expression of the IL-12, with no detectable IL-12
expression in the underlying tumor tissue using immunohistochemi-
cal and ELISA detection techniques. The discrepancy between
localization of IL-12 expression and tumor localization provides
evidence that IL-12 does not act directly on tumor cells, but instead
amplifies the inherent anti-tumor immune response. We have
shown that the mechanism of the inhibition of tumor growth by
mIL-12 gene therapy involves tumor apoptosis, rather than tumor
shrinkage by inhibition of proliferation. The increased numbers of
CD41 and CD81 lymphocytes in tumors after IL-12 gene gun
treatment and the markedly increased anti-tumor effects of IL-12
gene gun therapy in the immunocompetent mice, as opposed to mice
with natural killer cells but depleted of T lymphocytes, suggest that
T lymphocytes play a predominant role (Brunda et al, 1993; Nastala
et al, 1994; Rakhmilevich et al, 1996; Briscoe et al, 1997) in IL-12
induced apoptosis. Whereas direct cell killing can induce tumor cell
apoptosis, IL-12 gene therapy also increases the levels of both TNF-
α, which causes apoptosis directly, and IFN-γ, which augments the
TNF-α induced apoptosis. We speculate that the synergy of TNF-α
and IFN-γ (and perhaps unmeasured additional cytokines) is critical
in our model, and that production of IFN-γ alone is insufficient.
Although IL-12 protein administration in nude mice leads to five
times higher levels of IFN-γ in nude mice than in immunocompetent
mice (Brunda et al, 1993), IFN-γ is less efficacious in inhibiting tumor
growth than treatment with IL-12 protein (Brunda et al, 1995). Our
studies also show that EOMA cells are extremely sensitive to the
synergistic direct cytotoxic action of TNF-α and IFN-γ in vitro,
whereas IFN-γ alone has no cytotoxic activity against the EOMA
cells in vitro. In our in vivo model, the effect of TNF-α on the EOMA
cells in vivo may be heightened by the presence of IL-12, because IL-
12 itself directly enhances the immunotoxicity of TNF-α (Orange
et al, 1995), at least in part by inducing the expression of TNF-α
receptors (Jewett andBonavida, 1994).Thus, the lowbut significantly
increased tumor levels of TNF-α may have a profound effect on the
EOMA cells.
Systemic IL-12 protein therapy is poorly tolerated in both animal
and human trials (Brunda et al, 1993; Tahara et al, 1994; Lotze
et al, 1996). Theoretically, the localized and steady-state production
in vivo of IL-12 by gene therapy introduction would result in
higher local concentrations, lower systemic levels, and less systemic
toxicity. To achieve tumor volume reduction similar to that seen
in our mice, IL-12 protein 0.1–1 µg per d has been administered,
resulting in IFN-γ systemic levels of 3000–4000 pg per ml (Nastala
et al, 1994), in contrast to the maximal serum levels of 600 pg
IFN-γ per ml after two bombardments in our model. Although
IL-12 cDNA has not yet been administered to humans by the gene
gun approach, 15 humans with advanced malignancies injected
intratumorally with IL-12-transfected autologous fibroblasts pro-
ducing up to 100 ng IL-12 in 24 h have developed no untoward
effects, despite significant reduction of tumor sizes (Tahara et al,
1994). We have observed no evidence of apparent toxicity in IL-
12 or sham-transfected mice, as monitored by serial weights,
observation of behavior, and examination of viscera after termina-
tion. Although low circulating levels of IFN-γ and even TNF-α
were detectable after gene gun treatment in the mouse, it should
be recalled that the systemic levels generated in a 25 g mouse are
likely to be considerably higher than those achieved by local
cutaneous bombardment of the peritumoral area of a 5 kg human
infant, making peritumoral therapy even more attractive in the
infant for establishing efficacious local levels of cytokines. Indeed,
injection of IL-12 transfected fibroblasts in adult humans has
resulted in no detectable serum IL-12, despite a demonstrated anti-
tumor effect (Tahara et al, 1994).
The data presented in this study clearly show that gene gun
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therapy with IL-12 appears to limit the massive tumor overgrowth
and increase the survival of immunocompetent mice with primary
endothelial cell tumors. Given the cost, potential side-effects, and
occasional lack of efficacy of currently available medication for the
treatment of life-threatening primary vascular tumors, future trials
of gene gun administration of mIL-12 should be considered.
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